Delivery system for administration blood-glucose lowering drug
DCFirst Claim
Patent Images
1. A method for stimulating insulin secretion from the beta cells or pancreatic-islet tissue in a patient in need of insulin secretion, wherein the method comprises:
- (a) admitting orally into the patient a dosage form comprising;
(1) a wall comprising a member selected from the group consisting of a cellulose ester, cellulose ether and cellulose ester-ether, which will defines;
(2) a lumen;
(3) a first composition in the compartment comprising 1 mg to 100 mg of the drug N-[2-[4-[[[(cyclohexylamino) carbonyl]amino]sulfonyl]phenyl]ethyl]-5-methylpyrazinecarboxamide for stimulating insulin secretion and a pharmaceutically acceptable carrier therefore;
(4) a second composition in the compartment comprising a therapeutically acceptable hydrogel;
(5) an exit passageway in the wall for delivering the first composition from the lumen;
(b) imbibing fluid into the dosage form causing the first composition to provide a dispensable aqueous composition and the second composition to expand and push against the first composition, whereby the first composition is delivered from the dosage form; and
,(c) stimulating insulin secretion by delivering the first composition comprising 1 mg to 100 mg of the drug to the patient.
1 Assignment
Litigations
0 Petitions
Accused Products
Abstract
A dosage form is disclosed comprising the antidiabetic drug glipizide for administering to a patient in need of glipizide therapy.
-
Citations
2 Claims
-
1. A method for stimulating insulin secretion from the beta cells or pancreatic-islet tissue in a patient in need of insulin secretion, wherein the method comprises:
-
(a) admitting orally into the patient a dosage form comprising; (1) a wall comprising a member selected from the group consisting of a cellulose ester, cellulose ether and cellulose ester-ether, which will defines; (2) a lumen; (3) a first composition in the compartment comprising 1 mg to 100 mg of the drug N-[2-[4-[[[(cyclohexylamino) carbonyl]amino]sulfonyl]phenyl]ethyl]-5-methylpyrazinecarboxamide for stimulating insulin secretion and a pharmaceutically acceptable carrier therefore; (4) a second composition in the compartment comprising a therapeutically acceptable hydrogel; (5) an exit passageway in the wall for delivering the first composition from the lumen; (b) imbibing fluid into the dosage form causing the first composition to provide a dispensable aqueous composition and the second composition to expand and push against the first composition, whereby the first composition is delivered from the dosage form; and
,(c) stimulating insulin secretion by delivering the first composition comprising 1 mg to 100 mg of the drug to the patient.
-
-
2. An improvement in a dosage form for administering an antidiabetic drug to a patient, wherein the dosage form comprises:
-
(a) a wall comprising a member selected from the group consisting of a cellulose acylate, cellulose diacylate, cellulose triacylate, cellulose acetate, cellulose diacetate and cellulose triacetate, which wall defines; (b) a compartment; (c) a displacement composition in the compartment comprising a therapeutically acceptable hydrogen that absorbs fluid, expands and pushes a drug composition from the compartment; (d) an exit passageway in the wall for delivering a drug composition from the compartment; and
wherein the improvement comprises;(e) a drug composition in the compartment, said drug composition comprising 1 mg to 100 mg of substantially aqueous insoluble N-[2-[4-[[[(cyclohexylamino) carbonyl]amino]sulfonyl]phenyl]ethyl]-5-methylpyrazinecarboxamide and a pharmaceutically acceptable carrier therefore, which composition when in the presence of an aqueous fluid that enters the dosage form provides a dispensable aqueous composition that delivers 1 mg to 100 mg of the antidiabetic drug to the patient.
-
Specification